$2.24
7.44% yesterday
Nasdaq, Aug 12, 10:14 pm CET
ISIN
US12529R1077
Symbol
CCCC

C4 Therapeutics Inc Stock price

$2.24
-0.14 5.88% 1M
-1.06 32.12% 6M
-1.36 37.78% YTD
-3.48 60.84% 1Y
-10.06 81.79% 3Y
-16.76 88.21% 5Y
-16.76 88.21% 10Y
-16.76 88.21% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
-0.18 7.44%
ISIN
US12529R1077
Symbol
CCCC
Industry

Key metrics

Basic
Market capitalization
$172.2m
Enterprise Value
$-42.3m
Net debt
positive
Cash
$214.6m
Shares outstanding
71.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
5.0 | 6.6
EV/Sales
negative | negative
EV/FCF
0.5
P/B
1.0
Financial Health
Equity Ratio
61.8%
Return on Equity
-48.8%
ROCE
-49.0%
ROIC
-222.8%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$34.2m | $25.9m
EBITDA
$-121.6m | $-116.7m
EBIT
$-123.6m | $-128.8m
Net Income
$-111.6m | $-126.0m
Free Cash Flow
$-87.6m
Growth (TTM | estimate)
Revenue
16.5% | -27.2%
EBITDA
-6.1% | -1.1%
EBIT
-6.1% | -9.9%
Net Income
-3.4% | -19.7%
Free Cash Flow
-11.2%
Margin (TTM | estimate)
Gross
-
EBITDA
-355.2% | -450.4%
EBIT
-361.0%
Net
-325.9% | -486.5%
Free Cash Flow
-255.8%
More
EPS
$-1.6
FCF per Share
$-1.2
Short interest
6.2%
Employees
110
Rev per Employee
$320.0k
Show more

Is C4 Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

C4 Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a C4 Therapeutics Inc forecast:

9x Buy
75%
3x Hold
25%

Analyst Opinions

12 Analysts have issued a C4 Therapeutics Inc forecast:

Buy
75%
Hold
25%

Financial data from C4 Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
34 34
17% 17%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 40 40
1% 1%
118%
- Research and Development Expense 118 118
12% 12%
344%
-122 -122
6% 6%
-355%
- Depreciation and Amortization 1.99 1.99
12% 12%
6%
EBIT (Operating Income) EBIT -124 -124
6% 6%
-361%
Net Profit -112 -112
3% 3%
-326%

In millions USD.

Don't miss a Thing! We will send you all news about C4 Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

C4 Therapeutics Inc Stock News

Neutral
The Motley Fool
5 days ago
CCCC Revenue Drops 46%
Neutral
GlobeNewsWire
6 days ago
Cemsidomide Phase 1 Data in Multiple Myeloma Accepted as an Oral Presentation  at the International Myeloma Society (IMS) Annual Meeting; As of the July 23, 2025, Data Cutoff, Phase 1 ORR Remains at 40% at the 75 µg Dose Level and at 50% at the 100 µg Dose Level Productive Type C Meeting Held With FDA; Registrational Development of Cemsidomide in Multiple Myeloma on Track to Initiate in Early 2...
Positive
Seeking Alpha
about 2 months ago
CCCC's valuation is unjustifiably low, trading at half its liquidity despite a promising pipeline and no imminent cash crisis. Lead candidate cemsidomide shows encouraging early efficacy and tolerability in heavily pretreated multiple myeloma patients, with key data readouts expected in Q3 2025. Cost controls and restructuring have extended CCCC's cash runway into 2027, reducing dilution risk a...
More C4 Therapeutics Inc News

Company Profile

C4 Therapeutics, Inc. provides new class of targeted protein degradation. It develops Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Cambridge, MA.

Head office United States
CEO Andrew Hirsch
Employees 110
Founded 2015
Website c4therapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today